| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Dr. Halperin), SUNY, Stony Brook, NY; and the Section on Analytical Biochemistry (Dr. Heyes), Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD.
Although neurologic dysfunction occurs frequently in patients with Lyme borreliosis, it is rarely possible to demonstrate the causative organism within the neuraxis. This discordance could arise if neurologic symptoms were actually due to soluble neuromodulators produced in response to infection. Since immune stimulation is associated with the production of quinolinic acid (QUIN), an excitotoxin and N-methyl-D-aspartate (NMDA) agonist, we measured levels of CSF and serum QUIN, and lymphokines. Samples were obtained from 16 patients with CNS Borrelia burgdorferi infection, eight patients with Lyme encephalopathy (confusion without intra-CNS inflammation), and 45 controls. CSF QUIN was substantially elevated in patients with CNS Lyme and correlated strongly with CSF leukocytosis. In patients with encephalopathy, serum QUIN was elevated with corresponding increments in CSF QUIN. Lymphokine concentrations were not consistently elevated. We conclude that CSF QUIN is significantly elevated in B burgdorferi infection—dramatically in patients with CNS inflammation, less in encephalopathy. The presence of this known agonist of NMDA synaptic function—a receptor involved in learning, memory, and synaptic plasticity—may contribute to the neurologic and cognitive deficits seen in many Lyme disease patients.
Address correspondence and reprint requests to Dr. Melvyn P. Heyes, Section on Analytical Biochemistry, Laboratory of Clinical Science, Building 10, Room 3D40, National Institute of Mental Health, Bethesda, MD 20892.
Supported in part by grants from New York state for Lyme disease research and from the EEL and WHEEL Associations.
Received April 19, 1991. Accepted for publication in final form June 11, 1991.
This article has been cited by other articles:
|
|
 |
|
  J. R. Saper, A. E. Lake III, R. L. Hamel, T. E. Lutz, B. Branca, D. B. Sims, and M. M. Kroll Daily scheduled opioids for intractable head pain: Long-term observations of a treatment program Neurology, May 25, 2004; 62(10): 1687 - 1694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Valle, R. W. Price, A. Nilsson, M. Heyes, and D. Verotta CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy Brain, May 1, 2004; 127(5): 1047 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Costa, L. Steardo, and V. Cuomo Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects Pharmacol. Rev., March 1, 2004; 56(1): 103 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Heyes, R. J. Ellis, L. Ryan, M. E. Childers, I. Grant, T. Wolfson, S. Archibald, and T. L. Jernigan Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection Brain, May 1, 2001; 124(5): 1033 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M R JOHNSON, M R JOHNSON, J W A S SANDER, and J W A S SANDER The clinical impact of epilepsy genetics J. Neurol. Neurosurg. Psychiatry, April 1, 2001; 70(4): 428 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. D. Sheftell Pharmacologic Therapy, Nondrug Therapy, and Counseling Are Keys to Effective Migraine Management Arch Fam Med, August 1, 1993; 2(8): 874 - 879. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
